Earnings Summary

Bioxcel Therapeutics’s revenue jumped +Inf% since last year same period to $0.46Mn in the Q2 2023. On a quarterly growth basis, Bioxcel Therapeutics has generated 121.84% jump in its revenue since last 3-months.

Bioxcel Therapeutics’s net profit fell -42.06% since last year same period to $-53.52Mn in the Q2 2023. On a quarterly growth basis, Bioxcel Therapeutics has generated -1.36% fall in its net profits since last 3-months.

Bioxcel Therapeutics’s net profit margin jumped NaN% since last year same period to -11710.07% in the Q2 2023. On a quarterly growth basis, Bioxcel Therapeutics has generated 54.31% jump in its net profit margins since last 3-months.

Bioxcel Therapeutics’s earning per share (EPS) estimates for the current quarter stand at -1.41 - a -4.44% fall from last quarter’s estimates.

Bioxcel Therapeutics’s earning per share (EPS) estimates for the current year stand at -1.41.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Bioxcel Therapeutics’s return on assets (ROA) stands at -0.63.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Bioxcel Therapeutics’s return on equity (ROE) stands at -2.39.